
Anand Pathak MD PhD, MPH
Public Health & General Preventive Medicine
Medical Officer, FDA
Join to view full profile
10903 New Hampshire BlvdSilver Spring, MD 20993
Phone+1 513-313-8620
Dr. Pathak is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Anand Pathak is a preventive medicine specialist based in Silver Spring, MD, with subspecialties in public health and general preventive medicine. He completed a residency in public health and general preventive medicine at the University of Michigan and internal medicine residencies at Jewish Hospital of Cincinnati and Case Western Reserve University. He currently serves as a Medical Officer at the FDA and has previous experience as a Fellow at NCI Division of Cancer Epidemiology and Genetics. Dr. Pathak has published multiple articles, particularly related to FDA drug approval summaries, in reputable journals such as the Journal of Clinical Oncology and Clinical Cancer Research, gaining numerous citations. He was honored with induction into Phi Kappa Phi at the University of Michigan.
Education & Training
University of Michigan School of Public HealthResidency, Public Health and General Preventive Medicine, 2010 - 2012
Jewish Hospital of CincinnatiResidency, Internal Medicine, 2008 - 2009
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2007 - 2008
University of Cincinnati College of MedicineClass of 2007
Certifications & Licensure
MI State Medical License 2012 - 2028
American Board of Preventive Medicine Public Health & General Preventive Medicine
Awards, Honors, & Recognition
- University of Michigan Phi Kappa Phi Phi Kappa Phi
Publications & Presentations
PubMed
- 26 citationsUS Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locall...Asma Dilawari, James Buturla, Christy Osgood, Xin Gao, Wei Chen
Journal of Clinical Oncology. 2024-12-01 - 35 citationsUS Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative,-Mutated Advanced or Me...Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman, Mallorie H Fiero
Journal of Clinical Oncology. 2024-04-01 - 34 citationsFDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With-Mutated Metastatic Castration-Resistant Prostate Cancer.Jaleh Fallah, Jianjin Xu, Chana Weinstock, Michael H Brave, Erik Bloomquist
Journal of Clinical Oncology. 2024-02-10
Press Mentions
50% of Children with Cancer Are Left Undiagnosed and Untreated: StudyMarch 6th, 2019
Public Workshop - Next Generation Sequencing-Based Oncology Panels, February 25, 2016February 25th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: